Biomaterial Scaffolds: A Transformative Technology Still Waiting for Its Moment

Biomaterial scaffolds have been central to regenerative medicine and tissue engineering for decades, yet their routine clinical footprint—most visibly in orthopedic, cardiovascular, and neural applications—remains smaller than early forecasts suggested. Originally conceived as three-dimensional supportsfor cell adhesionand tissue ingrowth, scaffolds are now engineered as instructive microenvironments designed to influencecell fate throughmechanical, chemical, and architectural cues rather than merely providing structural support. Technical progress has been substantial; clinical translation has lagged. The principal bottleneck is no longer conceptual innovation but alignment of scaffold performance with biological heterogeneity, vascular integration, manufacturing reproducibility, reimbursement structures, and regulatory classification. Methodological challenges further complicate translation, as scaffold effects emerge through slow remodeling processes that complicate endpoint selection and limit cross-trial comparability. Advances in computational modeling, standardized characterization, imaging, and early regulatory engagement are beginning to narrow these gaps. Sustained clinical impact will depend on shifting emphasis from showcasing scaffold sophistication to demonstrating predictable, durable outcomes at scale.